Stock Market Update - February 10, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. QNCX - Quince Therapeutics, Inc.
Price: $0.5277 | Change: +305.92% ($0.3977)
QNCX just rocketed with an astounding 305.92% gain! What's behind this massive jump? Quince Therapeutics, Inc. experienced a substantial surge around February 11, 2026, after announcing they've engaged LifeSci Capital as their exclusive financial advisor. This firm will help Quince evaluate "strategic alternatives" – essentially, exploring options like partnerships, joint ventures, mergers, or even an acquisition – all with the goal of maximizing shareholder value.
This hopeful news comes on the heels of a very challenging time for Quince. Just a few weeks prior, on January 29, 2026, the stock plummeted after the company revealed its pivotal Phase 3 clinical trial for its drug eDSP failed to meet its goals, leading them to stop its development. Investors are now speculating that bringing in LifeSci Capital could signal a potential acquisition or other favorable strategic outcome is in the cards, sparking this dramatic increase in the stock's value.
2. JZXN - Jiuzi Holdings, Inc.
Price: $2.58 | Change: +89.71% ($1.22)
JZXN caught investors' attention with an impressive 89.71% gain. Jiuzi Holdings, Inc. saw its stock surge around early February 2026, primarily driven by a duo of significant investment announcements that injected substantial capital and new strategic direction into the company.
The biggest catalyst was a US$40 million commitment from crypto-focused investors, aimed at bolstering Jiuzi's global business and building out its Digital Asset Treasury in the digital finance space. Adding to the momentum, an additional US$30 million investment from Xinhui Solar will accelerate EV charging infrastructure development in Southeast Asia.
Together, these investments represent a clear strategic move towards both digital assets and the booming EV sector, backed by corporate actions like a planned reverse stock split to strengthen its Nasdaq standing.
3. EVMN - Evommune, Inc.
Price: $29.03 | Change: +70.87% ($12.04)
EVMN:NYSE saw an impressive jump of 70.87% recently. This significant surge around February 11, 2026, was primarily fueled by exciting news regarding their experimental drug, EVO301, designed to treat moderate-to-severe atopic dermatitis (a type of eczema).
Evommune announced positive top-line results from its Phase 2a trial, where EVO301 successfully met its main efficacy goal. The drug showed rapid and statistically significant improvements in skin condition (measured by EASI scores) compared to a placebo, along with a favorable safety profile. This validates the drug's mechanism and paves the way for further trials.
What makes this particularly interesting is how quickly several analysts reacted, raising their price targets for Evommune. This signals increased confidence in EVO301's potential to address a common and often challenging skin condition.
4. HURA - TuHURA Biosciences, Inc.
Price: $1.3 | Change: +60.47% ($0.4899)
HURA saw a whopping 60.47% gain around February 11, 2026, turning heads in the biotech sector.
This significant surge was primarily driven by TuHURA Biosciences receiving Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its lead drug candidate, IFx-2.0. Announced on February 2, 2026, this designation is for treating advanced cutaneous melanoma, a severe form of skin cancer. The FDA's decision was based on promising early study results that showed the drug was safe and showed clinical benefits in patients who had not responded to prior treatments.
Orphan Drug Designation is a major regulatory milestone, offering TuHURA several advantages, including potential market exclusivity for seven years if the drug receives final approval, along with tax credits and closer support from the FDA. This not only bolsters the drug's path forward but also strengthens its long-term commercial outlook, grabbing substantial attention from both retail investors and analysts.
5. FGL - Founder Group Limited Ordinary Shares
Price: $15.44 | Change: +55.96% ($5.54)
FGL recently posted an impressive 55.96% gain.
The primary driver behind this significant surge for Founder Group Limited Ordinary Shares (FGL:NASDAQ) was a 100-for-1 reverse stock split, which became effective on February 10, 2026. This corporate action essentially consolidated every 100 existing shares into one new share. The company undertook this move specifically to comply with Nasdaq's minimum bid price rule, aiming to increase its per-share price and avoid potential delisting.
A reverse stock split reduces the total number of outstanding shares, proportionally increasing the price of each remaining share. This allowed FGL to meet the exchange's listing requirements, illustrating how companies sometimes use corporate actions like this to maintain their market presence rather than reflecting a direct change in underlying business fundamentals.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.